“CMS confirmed recently that they will reimburse OSA if Plan D plans decides to lift it. And they have 180 days to make that decision from the FDA approval, and we're working with plans right now, and we anticipate to get some Medicare coverage by the second half of this year.”

In context

“bel. I know you've also filed for heart failure and how you expect that to play out over the course of the year? And then anything on next steps on the compounding litigation that we should be focused on? David Ricks: Dangerously close to a 2-part question there, Terence, but we'll go to Patrik to talk about access, and then I'll come back to Dan to make a quick comment about compounding. Patrik Jonsson: Thank you very much. When we look at the commercial access, it remains strong. We have 8% to 7% coverage in the commercial space still. And of course, the employer opt-in is a second step of high importance that made progress in 2024, and we expect in terms of employer opt-in that we are north of 50% today. OSA remains an opportunity for us to gain access also in the Medicare segment, and CMS confirmed recently that they will reimburse OSA if Plan D plans decides to lift it. And they have 180 days to make that decision from the FDA approval, and we're working with plans right now, and we anticipate to get some Medicare coverage by the second half of this year. And similarly, OSA is also an opportunity for us to get more Medicaid states signed in. We expect PIF when and if approved, to have a similar role as OSA, an access opportunity, particularly in Medicare and Medicaid. Daniel Skovronsky: Yes. So regarding compounding, I think our position has been pretty clear. We've been in supply since August and FDA took us off the list formally later in Q4. Of course, the compounding associations are suing to delay that. We opposed that and joined that suit. I think the next date coming up is February 18, where the FDA said that's when you need to stop one form of compounding. Our position has been clear all along. We don't think there's a place for this because we have full supply, and there's no reason to have non-approved kind of illegitimate product”